| [1] |
Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic immunohistochemical, and molecular genetic study of 1 765 cases with long-term follow-up [J]. Am J Surg Pathol, 2005, 29(1): 52-68.
|
| [2] |
Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor [J]. Hum Pathol, 2008, 39(10): 1411-1419.
|
| [3] |
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM [J]. Annals of Surgical Oncology, 2010, 17(6): 1471-1474.
|
| [4] |
Joensuu H, Hoenberger P, Corless CL. Gastrointestinal stromal tumour [J]. Lancet, 2013, 382(9896): 973-983.
|
| [5] |
Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts [J]. Lancet Oncol, 2012, 13(3): 265-274.
|
| [6] |
Raut CP, Espat NJ, Maki RG, et al. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate-or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial [J]. JAMA Oncol, 2018, 4(12): e184060.
|
| [7] |
Maki RG, Blay JY, Demetri GD, et al. Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion [J]. Oncologist, 2015, 20(7): 823-830.
|
| [8] |
Joensuu H, Wardelmann E, Sihto H, et al. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib An Exploratory Analysis of a Randomized Clinical Trial [J]. JAMA Oncol, 2017, 3(5): 602-609.
|
| [9] |
Lin J, Huang C, Zheng C, et al. Laparoscopic versus open gastric resection for larger than 5 cm primary gastric gastrointestinal stromal tumors (GIST): a size-matched comparison [J]. Surg Endosc, 2014, 28(9): 2577-2583.
|
| [10] |
Yoshihide Otani, Toshiharu Furukawa, Masashi Yoshida, et al. Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases [J]. Surgery, 2006, 139(4): 484-492.
|
| [11] |
Khoo CY, Goh BKP, Eng AKH, et al. Laparoscopic wedge resection for suspected large(≥5 cm) gastric gastrointestinal stromal tumors [J]. Surgery Endoscopy And Other Interventional Techniques, 2017, 31(5): 2271-2279.
|
| [12] |
Yin X, Yin Y, Chen H, et al. Comparison analysis of three different types of minimally invasive procedures for gastrointestinal stromal tumors≤5 cm [J]. Journal of Laparoendoscopic & Advanced Surgical Techniques, 2018, 28(1): 58-64.
|
| [13] |
Shen C, Chen H, Yin Y, et al. Endoscopic Versus Open Resection for Small Gastric Gastrointestinal Stromal Tumors [J]. Medicine, 2015, 94(1): e376.
|
| [14] |
Chen T, Zhou PH, Chu Y, et al. Long-term Outcomes of Submucosal Tunneling Endoscopic Resection for Upper Gastrointestinal Submucosal Tumors [J]. Annals of Surgery, 2017, 265(2): 363-369.
|
| [15] |
Cai Z, Yin Y, Shen C, et al. Role of surgical resection for patients with recurrent or metastatic gastrointestinal stromal tumors: a systematic review and meta-analysis [J]. International Journal of Surgery, 2018, (56): 108-114.
|
| [16] |
Li J, Ye Y, Wang J, et al. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor [J]. Chin J Cancer Res, 2017, 29(4): 281-293.
|
| [17] |
Shen C, Chen H, Yin Y, et al. Preoperative imatinib for patients with primaryunresectable or metastatic/recurrent gastrointestinal stromal tumor [J]. Clinics, 2014, 69(11): 758-762.
|
| [18] |
Tang S, Yin Y, Shen C, et al. Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST) [J]. World J Surg Oncol, 2017, 15(1): 79.
|
| [19] |
Yin Y, Xiang J, Tang S, et al. A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment [J]. Medicine, 2016, 95(49): e5488.
|
| [20] |
Dong-Hoe K, Min-Hee R, Kyoung-Mee K, et al. Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor [J]. Cancer Res Treat, 2016, 48(4): 1155-1166.
|
| [21] |
Mehren MV, Randall RL, Benjamin RS, et al. Soft Tissue Sarcoma, Version 2.2016, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2016, 14(6): 758-786.
|
| [22] |
Shen C, Chen H, Yin Y, et al. Endoscopic versus open resection for small gastric gastrointestinal stromal tumors: safety and outcomes [J]. Medicine, 2015, 94(1): e376.
|
| [23] |
Wagner AJ, Kindler H, Gelderblom H, et al. A phase II study of a human anti-PDGFRa monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors [J]. Annals of Oncology, 2017, 28(3): 541-546.
|
| [24] |
Joensuu H, Eriksson M, Hall KS, et al. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib [J]. Cancer, 2014, 120(15): 2325-2333.
|
| [25] |
Dematteo RP, Ballman KV, Antonescu CR, et al. adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumour: a randomized, double-blind, placebo-controlled trial [J]. Lancet, 2009, 373(9669): 1097-1104.
|